CSIMarket
 
Biophytis Sa  (NASDAQ: BPTS)
Other Ticker:  
 
 
Price: $8.2200 $-1.48 -15.285%
Day's High: $8.96 Week Perf: -29.16 %
Day's Low: $ 8.05 30 Day Perf: -46.2 %
Volume (M): 19 52 Wk High: $ 24.00
Volume (M$): $ 152 52 Wk Avg: $16.03
Open: $8.24 52 Wk Low: $8.05



 Market Capitalization (Millions $) 112
 Shares Outstanding (Millions) 14
 Employees 20
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 12
 Capital Exp. (TTM) (Millions $) 0

Biophytis Sa
Biophytis SA is a clinical-stage biotechnology company based in France. The company focuses on developing innovative therapeutics to treat age-related diseases, with a particular focus on neuromuscular and metabolic diseases. Biophytis is known for its expertise in the field of mitochondria, which are often implicated in age-related conditions.

The company's lead product candidate is Sarconeos (BIO101), which is being developed for the treatment of sarcopenia, a progressive decline in muscle mass, strength, and function that occurs with aging. Sarconeos is currently in Phase 2b/3 clinical trials and has shown promising results in improving muscle function in patients with sarcopenia.

Biophytis has also developed other drug candidates targeting various age-related diseases, including Macuneos (BIO201) for the treatment of dry age-related macular degeneration and COVA (BIO34) for the treatment of COVID-19 patients with respiratory failure. These drug candidates are in preclinical or early clinical stages of development.

Overall, Biophytis SA is dedicated to advancing the field of biotechnology and developing innovative therapies to address the unmet needs of aging populations.


   Company Address: Sorbonne University?BC 9 Paris 75005
   Company Phone Number: 1 44 27 23 00   Stock Exchange / Ticker: NASDAQ BPTS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        1.33% 
AZN        1.27% 
BMY   -2.94%    
JNJ        1.24% 
MRK   -3.92%    
PFE   -1.31%    
• View Complete Report
   



Vanda Pharmaceuticals Inc

Deficit bigger than a year before at VNDA amid the October to December 31 2024 period

For the October to December 31 2024 period company Deficit has extended of $-0.08 per share compare to $-0.04 a year before and earnings per share improved from $-0.09 per share from the preceding reporting period. The revenue inched up admirably by 17.481 % to $53.19 million from $45.27 million in the similar reporting period a year before and sequentially revenue advanced by 11.614 % from $47.65 million. Vanda Pharmaceuticals Inc s' top-line, surge in the fourth quarter of 2024 measures positively to its Major Pharmaceutical Preparations industry contemporaries, which reported all in all 5.46 % revenue rise during the matching time thus far.

Abbvie Inc

Shortfall In spite of revenue growth at the company amid the October to December 31 2024 period

For the fourth quarter of 2024 Abbvie Inc slipped into shortfall of $-0.01 per share compare to $0.46 a year before and earnings per share fell from $0.88 per share from the prior reporting season. The Revenue grew by 5.601 % to $15.10 billion from $14.30 billion in the corresponding reporting season a year before and sequentially revenue grew by 4.44 % from $14.46 billion. Major Pharmaceutical Preparations company's top-line, surge in the fourth quarter of 2024 compares positively to its Major Pharmaceutical Preparations sector contemporaries, which experienced overall 5.46 % revenue growth during the matching time yet.

Nanoviricides Inc

Nanoviricides Inc reported operating deficit in the second quarter of 2025

While the October to December 31 2024 reporting cycle goes on, many entities have reported their results. In the thick of it, are multiple constituents of the Major Pharmaceutical Preparations industry. As well as, today, NNVC published operating deficit of $-2.059051 million, for the financial second quarter of 2025.

Benitec Biopharma Inc

The company disclosed operating shortfall in the second quarter of 2024

The Major Pharmaceutical Preparations sector insiders begin to interpret the second quarter of 2024 earnings. Presently they follow operating shortfall of $-8.61 million, from the company, as it hasn't mentioned any revenue thus far, for the own October to December 31 2024 quarter.

Edesa Biotech Inc

The rising corporation from the Major Pharmaceutical Preparations market the Edesa Biotech Inc issued the October to December 31 2024 period, results

As the earnings season of the October to December 31 2024 resumes, many businesses have announced the respective earnings. Among them, have been several constituents of the Major Pharmaceutical Preparations sector. And today, Edesa Biotech Inc reported operating deficit of $-1.898689 million, for the fiscal first quarter of 2025.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com